ARRAY BIOPHARMA INC Form DEFA14A September 14, 2012

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### INFORMATION REQUIRED IN PROXY STATEMENT

# **SCHEDULE 14A INFORMATION**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Filed by the Registrant X

Filed by a Party other than the Registrant O

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o

**Definitive Proxy Statement** o **Definitive Additional Materials** Х

Soliciting Material Pursuant to §240.14a-12

Array BioPharma Inc. (Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Provy Statement, if other than the Registrant)

(4)

Date Filed:

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)				
Payment of Filing Fee (Check the appropriate box):				
X	No fee required.	required.		
0	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.			
	(1)		Title of each class of securities to which transaction applies:	
	(2)		Aggregate number of securities to which transaction applies:	
	(3)		Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):	
	(4)		Proposed maximum aggregate value of transaction:	
	(5)		Total fee paid:	
0	Check box if any part	id previously with preliminary materials. box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the ing fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the of its filing.  Amount Previously Paid:		
	(2)	Form, Schedule or Registration	on Statement No.:	
	(3)	Filing Party:		